<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36323511</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>Senescent-like Blood Lymphocytes and Disease Progression in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e200042</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000200042</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">Aging is known to exacerbate neuroinflammation, and in the neurodegenerative disorder amyotrophic lateral sclerosis (ALS), an older age is associated with a worse prognosis. We have previously shown the activation of cell senescence pathways in the proteome of peripheral blood mononuclear cells and the increase of proinflammatory cytokines in blood from individuals living with ALS. In this single-center, retrospective study, we investigated the expression of senescent-like blood mononuclear cells in ALS.</AbstractText><AbstractText Label="METHODS">We first applied multidimensional cytometry by time-of-flight (CyTOF) to study the senescent immunophenotype of blood mononuclear cells from 21 patients with ALS and 10 healthy controls (HCs). We then used targeted flow cytometry (FC) to investigate frequencies of senescent blood lymphocytes in 40 patients with ALS and 20 HCs. Longitudinal analysis included 2 additional time points in 17 patients with ALS. Frequencies of senescent-like lymphocytes were analyzed in relation to survival.</AbstractText><AbstractText Label="RESULTS">Unsupervised clustering of CyTOF data showed higher frequencies of senescent CD4<sup>+</sup>CD27<sup>-</sup>CD57<sup>+</sup> T cells in patients with ALS compared with those in HCs (<i>p</i> = 0.0017, false discovery (FDR)-adjusted <i>p</i> = 0.029). Moderate to strong negative correlations were identified between CD4 T central memory-cell frequencies and survival (R = -061, <i>p</i> = 0.01; FDR-adjusted <i>p</i> &lt; 0.1) and between CD95 CD8 cells and ALS functional rating scale revised at baseline (R = -0.72, <i>p</i> = 0.001; FDR-adjusted <i>p</i> &lt; 0.1).Targeted FC analysis showed higher memory T regulatory cells (<i>p</i> = 0.0052) and memory CD8<sup>+</sup> T cell (M-Tc; <i>p</i> = 0.0006) in bulbar ALS (A-B) compared with those in limb ALS (A-L), while late memory B cells (LM-B) were also elevated in A-B and fast-progressing ALS (<i>p</i> = 0.0059). Higher M-Tc levels separated A-B from A-L (AUC: 0.887; <i>p</i> &lt; 0.0001). A linear regression model with prespecified clinical independent variables and neurofilament light chain plasma concentration showed that higher frequencies of LM-B predicted a shorter survival (hazard ratio: 1.094, CI: 1.026-1.167; <i>p</i> = 0.006).</AbstractText><AbstractText Label="DISCUSSION">Our data suggest that a systemic elevation of senescent and late memory T and B lymphocytes is a feature of faster progressing ALS and of ALS individuals with bulbar involvement. Lymphocyte senescence and their memory state may be central to the immune dysregulation known to drive disease progression in ALS and a target for biomarkers and therapeutics discovery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yildiz</LastName><ForeName>Ozlem</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Trauma Centre (O.Y., A.M.), Blizard Institute, Barts and The London School of Medicine &amp; Dentistry, Queen Mary University of London; Queen Square Motor Neuron Disease Centre (A.M.), Neuromuscular Department, Institute of Neurology, University College London; Translational Medicine and Therapeutics (J.S., S.M.H.), William Harvey Research Institute, Barts and the London, Queen Mary University of London; Department of Immunobiology (T.T.), School of Immunology &amp; Microbial Sciences, King's College London; Nuffield Department of Clinical Neurosciences (M.R.T.), University of Oxford; and Sheffield Institute for Translational Neuroscience (P.J.S.), University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroth</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Trauma Centre (O.Y., A.M.), Blizard Institute, Barts and The London School of Medicine &amp; Dentistry, Queen Mary University of London; Queen Square Motor Neuron Disease Centre (A.M.), Neuromuscular Department, Institute of Neurology, University College London; Translational Medicine and Therapeutics (J.S., S.M.H.), William Harvey Research Institute, Barts and the London, Queen Mary University of London; Department of Immunobiology (T.T.), School of Immunology &amp; Microbial Sciences, King's College London; Nuffield Department of Clinical Neurosciences (M.R.T.), University of Oxford; and Sheffield Institute for Translational Neuroscience (P.J.S.), University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tree</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Trauma Centre (O.Y., A.M.), Blizard Institute, Barts and The London School of Medicine &amp; Dentistry, Queen Mary University of London; Queen Square Motor Neuron Disease Centre (A.M.), Neuromuscular Department, Institute of Neurology, University College London; Translational Medicine and Therapeutics (J.S., S.M.H.), William Harvey Research Institute, Barts and the London, Queen Mary University of London; Department of Immunobiology (T.T.), School of Immunology &amp; Microbial Sciences, King's College London; Nuffield Department of Clinical Neurosciences (M.R.T.), University of Oxford; and Sheffield Institute for Translational Neuroscience (P.J.S.), University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Trauma Centre (O.Y., A.M.), Blizard Institute, Barts and The London School of Medicine &amp; Dentistry, Queen Mary University of London; Queen Square Motor Neuron Disease Centre (A.M.), Neuromuscular Department, Institute of Neurology, University College London; Translational Medicine and Therapeutics (J.S., S.M.H.), William Harvey Research Institute, Barts and the London, Queen Mary University of London; Department of Immunobiology (T.T.), School of Immunology &amp; Microbial Sciences, King's College London; Nuffield Department of Clinical Neurosciences (M.R.T.), University of Oxford; and Sheffield Institute for Translational Neuroscience (P.J.S.), University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Trauma Centre (O.Y., A.M.), Blizard Institute, Barts and The London School of Medicine &amp; Dentistry, Queen Mary University of London; Queen Square Motor Neuron Disease Centre (A.M.), Neuromuscular Department, Institute of Neurology, University College London; Translational Medicine and Therapeutics (J.S., S.M.H.), William Harvey Research Institute, Barts and the London, Queen Mary University of London; Department of Immunobiology (T.T.), School of Immunology &amp; Microbial Sciences, King's College London; Nuffield Department of Clinical Neurosciences (M.R.T.), University of Oxford; and Sheffield Institute for Translational Neuroscience (P.J.S.), University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henson</LastName><ForeName>Sian M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Trauma Centre (O.Y., A.M.), Blizard Institute, Barts and The London School of Medicine &amp; Dentistry, Queen Mary University of London; Queen Square Motor Neuron Disease Centre (A.M.), Neuromuscular Department, Institute of Neurology, University College London; Translational Medicine and Therapeutics (J.S., S.M.H.), William Harvey Research Institute, Barts and the London, Queen Mary University of London; Department of Immunobiology (T.T.), School of Immunology &amp; Microbial Sciences, King's College London; Nuffield Department of Clinical Neurosciences (M.R.T.), University of Oxford; and Sheffield Institute for Translational Neuroscience (P.J.S.), University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Neuroscience and Trauma Centre (O.Y., A.M.), Blizard Institute, Barts and The London School of Medicine &amp; Dentistry, Queen Mary University of London; Queen Square Motor Neuron Disease Centre (A.M.), Neuromuscular Department, Institute of Neurology, University College London; Translational Medicine and Therapeutics (J.S., S.M.H.), William Harvey Research Institute, Barts and the London, Queen Mary University of London; Department of Immunobiology (T.T.), School of Immunology &amp; Microbial Sciences, King's College London; Nuffield Department of Clinical Neurosciences (M.R.T.), University of Oxford; and Sheffield Institute for Translational Neuroscience (P.J.S.), University of Sheffield, UK. a.malaspina@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BRC-1215-20017</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NF-SI-0617-10077</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>21</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36323511</ArticleId><ArticleId IdType="pmc">PMC9673751</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000200042</ArticleId><ArticleId IdType="pii">10/1/e200042</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C, Bonetto V, Pupillo E, et al. . Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7-8):485-495. doi: 10.1080/21678421.2020.1779298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1779298</ArticleId><ArticleId IdType="pubmed">32583689</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Halliday GM, Kiernan MC, Tan RH. TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansions. Neurology. 2019;593(19):e1748-e1755.</Citation><ArticleIdList><ArticleId IdType="pubmed">31619481</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS genes in the genomic era and their implications for FTD. Trends Genet. 2018;34(6):404-423.</Citation><ArticleIdList><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, McMillan CT, Brettschneider J, et al. . Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(2):163-169. doi: 10.1136/jnnp-2012-303507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303507</ArticleId><ArticleId IdType="pmc">PMC3543474</ArticleId><ArticleId IdType="pubmed">23117491</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, et al. . ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2(5):e89530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137(5):715-730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina A, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int Immunol. 2015;27(3):117-129.</Citation><ArticleIdList><ArticleId IdType="pubmed">25344935</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubiri I, Lombardi V, Bremang M, et al. . Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol Neurodegener. 2018;13(1):60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6223075</ArticleId><ArticleId IdType="pubmed">30404656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Allen K, Oei F, et al. . Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(4):e244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelson N, Facciponte D, Bradley W, Stommel E. Cytokine expression levels in ALS: a potential link between inflammation and BMAA-triggered protein misfolding. Cytokine Growth Factor Rev. 2017;37:81-88.</Citation><ArticleIdList><ArticleId IdType="pubmed">28532674</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Chang C, Qin XY, et al. . Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep. 2017;7(1):9094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen MN, Wuolikainen A, Nilsson AC. Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis. Neurol Neuroimmunology Neuroinflammation. 2020;7(3):e697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136052</ArticleId><ArticleId IdType="pubmed">32123048</ArticleId></ArticleIdList></Reference><Reference><Citation>Deursen JM. The role of senescent cells in ageing. Nature. 2014;22509(7501):439-446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4214092</ArticleId><ArticleId IdType="pubmed">24848057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D, Baloh RH. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J Clin Invest. 2017;127(9):3250-3258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669558</ArticleId><ArticleId IdType="pubmed">28737506</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccoli T, Partridge L, Isaacs AM. Ageing as a risk factor for ALS/FTD. Hum Mol Genet. 2017;26(R2):R105-R113.</Citation><ArticleIdList><ArticleId IdType="pubmed">28977441</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou N, Yang Y, Scott IC, Lou X. The Sec domain protein Scfd1 facilitates trafficking of ECM components during chondrogenesis. Dev Biol. 2017;421(1):8-15.</Citation><ArticleIdList><ArticleId IdType="pubmed">27851892</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccoli T, Partridge L, Isaacs AM. Ageing as a risk factor for ALS/FTD. Hum Mol Genet. 2017;26(R2). R105-R113. 10.1093/hmg/ddx247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx247</ArticleId><ArticleId IdType="pubmed">28977441</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulop T, Larbi A, Dupuis G, et al. . Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2018;8:1960. 10.3389/fimmu.2017.01960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01960</ArticleId><ArticleId IdType="pmc">PMC5767595</ArticleId><ArticleId IdType="pubmed">29375577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S, Wang C, Mao X, Yi H. B cell dysfunction associated with aging and autoimmune diseases. Front Immunol. 2019;10:318. 10.3389/fimmu.2019.00318.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00318</ArticleId><ArticleId IdType="pmc">PMC6400972</ArticleId><ArticleId IdType="pubmed">30873171</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca D. Senescent B cells in aging and age-related diseases: their role in the regulation of antibody responses. Exp Gerontol. 2018;107:55-58. doi: 10.1016/j.exger.2017.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2017.07.002</ArticleId><ArticleId IdType="pmc">PMC5754260</ArticleId><ArticleId IdType="pubmed">28687479</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2000;1(5):293-299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1-2):13-21. doi: 10.1016/s0022-510x(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing: R Foundation for Statistical Computing; 2021. R-project.org/.</Citation></Reference><Reference><Citation>Bodenheimer T, Halappanavar M, Stuart J, et al. . FastPG: fast clustering of millions of single cells. bioRxiv. 2120. 10.1101/2020.06.19.159749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.19.159749</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Song W, Wong BY, et al. . A comparison framework and guideline of clustering methods for mass cytometry data. Genome Biol. 2019;20(1):297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929440</ArticleId><ArticleId IdType="pubmed">31870419</ArticleId></ArticleIdList></Reference><Reference><Citation>Linderman GC, Rachh M, Hoskins JG, Steinerberger S, Kluger Y. Fast interpolation-based t-SNE for improved visualization of single-cell RNA-seq data. Nat Methods. 2019;16(3):243-245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402590</ArticleId><ArticleId IdType="pubmed">30742040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobak D, Berens P. The art of using t-SNE for single-cell transcriptomics. Nat Commun. 2019;10(1):5416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6882829</ArticleId><ArticleId IdType="pubmed">31780648</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun ATL, Richard AC, Marioni JC. Testing for differential abundance in mass cytometry data. Nat Methods. 2017;14(7):707-709. doi: 10.1038/nmeth.4295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4295</ArticleId><ArticleId IdType="pmc">PMC6155493</ArticleId><ArticleId IdType="pubmed">28504682</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139-140. doi: 10.1093/bioinformatics/btp616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Yosef H. Controlling the false discovery rate: a practical and powerful approach to multiple testing. R Stat Soc. 1995;10.1111/j.2517-6161.1995.tb02031.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. . Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95(1):e59-e69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeland MR, Andorf S, Manohar M, et al. . MA cytometry reveals cellular fingerprint associated with IgE+ peanut tolerance and allergy in early life. Nat Commun. 2020;11(1):1091. 10.1038/s41467-020-14919-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-14919-4</ArticleId><ArticleId IdType="pmc">PMC7046671</ArticleId><ArticleId IdType="pubmed">32107388</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5-6):303-309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni E, Bremang M, Mitra V, et al. . Combined tissue-fluid proteomics to unravel phenotypic variability in amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):4478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6418138</ArticleId><ArticleId IdType="pubmed">30872628</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyema OO, Njemini R, Bautmans I, Renmans W, De Waele M, Mets T. Cellular aging and senescence characteristics of human T-lymphocytes. Biogerontology. 2012;13(2):169-181.</Citation><ArticleIdList><ArticleId IdType="pubmed">22102004</ArticleId></ArticleIdList></Reference><Reference><Citation>Henson SM, Macaulay R, Franzese O, Akbar AN. Reversal of functional defects in highly differentiated young and old CD8 T cells by PDL blockade. Immunology. 2012;135(4):355-363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372750</ArticleId><ArticleId IdType="pubmed">22211948</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenchley JM, Karandikar NJ, Betts MR, et al. . Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+T cells. Blood. 2003;101(7):2711-2720.</Citation><ArticleIdList><ArticleId IdType="pubmed">12433688</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbar SMH, Arne N. KLRG1&#x2014;more than a marker for T cell senescence. Age (Dordr). 2009;31(4):285-291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813054</ArticleId><ArticleId IdType="pubmed">19479342</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lee MH, Henderson L, et al. . Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. 2015;7(307):307ra153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344353</ArticleId><ArticleId IdType="pubmed">26424568</ArticleId></ArticleIdList></Reference><Reference><Citation>Autio A, Nevalainen T, Mishra BH, Jylh&#xe4; M, Flinck H, Hurme M. Effect of aging on the transcriptomic changes associated with the expression of the HERV-K (HML-2) provirus at 1q22. Immun Aging. 2020;17:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7218820</ArticleId><ArticleId IdType="pubmed">32435269</ArticleId></ArticleIdList></Reference><Reference><Citation>Laderoute MP. A new paradigm about HERV-K102 particle production and blocked release to explain cortisol mediated immunosenescence and age-associated risk of chronic disease. Discov Med. 2015;20(112):379-391.</Citation><ArticleIdList><ArticleId IdType="pubmed">26760982</ArticleId></ArticleIdList></Reference><Reference><Citation>Naor S, Zohar K, Bronshtein T, Goren E, Machluf M, Melamed D. Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. J Neurol. 2009;256(8):1228-1235.</Citation><ArticleIdList><ArticleId IdType="pubmed">19280101</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, G&#xfc;nther R, Akg&#xfc;n K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):5941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125229</ArticleId><ArticleId IdType="pubmed">32246039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Wang X, Ragonnaud E, et al. . Therapeutic B-cell depletion reverses progression of Alzheimer's disease. Nat Commun. 2021;12(1):2185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8042032</ArticleId><ArticleId IdType="pubmed">33846335</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakkas LI, Bogdanos DP, Kousvelari EE. Loss of C9orf72 function leads to autoimmunity. Ann Transl Med. 2017;5(3):60. doi: 10.21037/atm.2017.01.33.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2017.01.33</ArticleId><ArticleId IdType="pmc">PMC5326657</ArticleId><ArticleId IdType="pubmed">28251139</ArticleId></ArticleIdList></Reference><Reference><Citation>Niebroj-Dobosz I, Janik P, Jamrozik Z, Kwiecinski H. Immunochemical quantification of glycoconjugates in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients. Eur J Neurol. 1999;6(3):335-340.</Citation><ArticleIdList><ArticleId IdType="pubmed">10210915</ArticleId></ArticleIdList></Reference><Reference><Citation>Offen D, Halevi S, Orion D, et al. . Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology. 1998;51(4):1100-1103.</Citation><ArticleIdList><ArticleId IdType="pubmed">9781536</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes F, Topping J, Kuhle J, et al. . Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(3):274-278.</Citation><ArticleIdList><ArticleId IdType="pubmed">24078718</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes F, Lombardi V, Lu C-H, et al. . Humoral response to neurofilaments and dipeptide repeats in ALS progression. Annal Clin Translational Neurol. 2021;8(9):1831-1844. 10.1002/acn3.51428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51428</ArticleId><ArticleId IdType="pmc">PMC8419401</ArticleId><ArticleId IdType="pubmed">34318620</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>